Detalhe da pesquisa
1.
First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma.
Cancer Immunol Immunother
; 71(2): 417-431, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-34216247
2.
Pharmacokinetics of Tacrolimus and Cyclosporine in Liver Transplant Recipients Receiving 3 Direct-Acting Antivirals as Treatment for Hepatitis C Infection.
Ther Drug Monit
; 38(5): 640-5, 2016 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27310199
3.
Dose Optimization in Oncology Drug Development: An International Consortium for Innovation and Quality in Pharmaceutical Development White Paper.
Clin Pharmacol Ther
; 2024 May 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38752712
4.
Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer.
J Clin Oncol
; 41(5): 1105-1115, 2023 02 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36288547
5.
A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC.
JTO Clin Res Rep
; 3(1): 100262, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-35005654
6.
Crystallographic analysis of human hemoglobin elucidates the structural basis of the potent and dual antisickling activity of pyridyl derivatives of vanillin.
Acta Crystallogr D Biol Crystallogr
; 67(Pt 11): 920-8, 2011 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-22101818
7.
Phase 1 study of telisotuzumab vedotin in Japanese patients with advanced solid tumors.
Cancer Med
; 10(7): 2350-2358, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33675179
8.
Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma.
Clin Cancer Res
; 27(21): 5781-5792, 2021 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34426443
9.
Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancer.
Cancer Treat Res Commun
; 28: 100405, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34329846
10.
Model Informed Dosing Regimen and Phase I Results of the Anti-PD-1 Antibody Budigalimab (ABBV-181).
Clin Transl Sci
; 14(1): 277-287, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32770720
11.
Assessment of Clinical Drug-Drug Interactions of Elagolix, a Gonadotropin-Releasing Hormone Receptor Antagonist.
J Clin Pharmacol
; 60(12): 1606-1616, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33045114
12.
Exposure-response evaluations of venetoclax efficacy and safety in patients with non-Hodgkin lymphoma.
Leuk Lymphoma
; 59(4): 871-879, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28797193
13.
Industry Perspective on Standardizing Food-Effect Studies for New Drug Development.
Clin Pharmacokinet
; 57(8): 901-909, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29460023
14.
First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.
J Clin Oncol
; 36(33): 3298-3306, 2018 11 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-30285518
15.
Effect of co-medications on paritaprevir, ritonavir, ombitasvir, dasabuvir and ribavirin pharmacokinetics: analysis of data from seven Phase II/III trials.
Antivir Ther
; 21(8): 707-714, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27584548
16.
Are Clinical Therapeutic Protein-Drug Interaction Studies Needed When Disease Modification Is Driving the Potential Interaction?
J Clin Pharmacol
; 58(10): 1371-1372, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30129669